METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise against fatty liver cirrhosis
Disease control OngoingThis study tests an experimental drug called efinopegdutide in 80 adults with liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can lower liver fat, inflammation, and scarring compared …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
500 obese patients tracked to unlock secrets of weight loss
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 500 adults with obesity who are trying to lose weight. Researchers collect information like body measurements, blood tests, and lifestyle habits to find out what helps people succeed. The goal is to create personalized weight loss plans based on each person's u…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated May 06, 2026 16:03 UTC